Skip to main content
Premium Trial:

Request an Annual Quote

MNG Laboratories Carrier Exome

MNG Laboratories has introduced the MNG Carrier Exome, a test to determine carrier status for recessive disorders like cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. The test is designed to detect a wide range of rare family or sub-population specific variants that could have an adverse effect in offspring. Whole exome sequencing is performed on both partners in order to detect shared known pathogenic and predicted disruptive variants in genes that are causative of autosomal recessive disorders. This test is intended for prospective parents who are interested in the most complete review of their genetic background to better understand their risk of having children with rare autosomal recessive disorders. It is not recommended for diagnostic purposes.

In addition to the MNG Carrier Exome, MNG Laboratories is launching a Pan-European Carrier Screen test and an Ashkenazi Jewish Carrier Screen test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.